Anthem Biosciences IPO
Anthem Biosciences IPO is a book building of ₹3,395.00 crores. The issue is a combination of fresh issue of 0.00 crore shares aggregating to ₹0.00 crores and offer for sale of 0.00 crore shares aggregating to ₹3,395.00 crores.
Anthem Biosciences IPO dates are yet to be announced. The allotment for the Anthem Biosciences IPO is expected to be finalized on [.].
Anthem Biosciences IPO Details
| IPO Date | to |
| Listing Date | [.] |
| Face Value | ₹2 per share |
| Issue Price Band | [.] to [.] per share |
| Lot Size | |
| Sale Type | Offer For Sale |
| Total Issue Size | 0 shares (aggregating up to ₹3,395.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 55,90,77,100 shares |
Anthem Biosciences IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50.00% of the Net Issue |
| Retail Shares Offered | Not less than 35.00% of the Net Issue |
| NII Shares Offered | Not less than 15.00% of the Net Issue |
Anthem Biosciences IPO Timeline (Tentative Schedule)
Anthem Biosciences IPO opens on , and closes on .
| IPO Open Date | |
| IPO Close Date | |
| Cut-off time for UPI mandate confirmation | 5 PM on |
Anthem Biosciences IPO Promoter Holding
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.
| Share Holding Pre Issue | 77.23% |
| Share Holding Post Issue |
About Anthem Biosciences Limited
Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.
The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.
The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.
As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.
As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.
As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.
Competitive Strength
- One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO.
- Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
- Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
- Long-standing relationships with a large, diversified and loyal customer base.
- Professional and experienced leadership team supported by a qualified scientific talent pool.
Company Financials
Anthem Biosciences Limited Financial Information (Restated)
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 2,692.51 | 2,398.11 | 2,014.46 | 1,618.87 |
| Revenue | 910.85 | 1,483.07 | 1,133.99 | 1,280.24 |
| Profit After Tax | 244.31 | 367.31 | 385.19 | 405.54 |
| EBITDA | 327.50 | 519.96 | 446.05 | 587.31 |
| Net Worth | 2,204.37 | 1,924.66 | 1,740.67 | 1,355.00 |
| Reserves and Surplus | 2,095.49 | 1,815.39 | 1,628.88 | 1,347.64 |
| Total Borrowing | 131.26 | 232.53 | 125.06 | 35.49 |
| Amount in ₹ Crore | ||||
Key Performance Indicator (KPI)
| KPI | Values |
|---|---|
| ROE | 20.04% |
| ROCE | 25.22% |
| Debt/Equity | 0.12 |
| RoNW | 20.03% |
| PAT Margin | 24.77% |
| EBITDA Margin | 36.25% |
Show More See the Oswal Pumps’ IPO RHP for additional information. For the most recent information on the current IPO, future IPOs, IPO GMP, today’s IPO GMP, or the IPO Allotment Status, please visit our website at newipo.info. For investors, our trustworthy website provides a number of advantages.